1 patent currently held
10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Oct 2036. from the record
Of the 10 now held by other companies, 9 name B3AR Therapeutics Inc. as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2036
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Oct 2031 · High confidence
The most cited patent in this portfolio, cited by 28 later US patents, top 25% of utility patents granted in 2016 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
now held by B3AR Therapeutics, Inc.
Also notable
Ends Dec 2035 · High confidence
Cited by 22 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by B3AR Therapeutics, Inc.
Also notable
Ends Oct 2036 · Medium confidence
A family of 5 related applications built on the 2019 grant. Protection runs to 2036.
now held by B3AR Therapeutics, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- 1 term has ended since Aug 23, 2026
- Sep 4 US 10,065,922 Solabegron Zwitterion and Uses Thereof · lapsed on the fee record
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Solabegron Zwitterion and Uses Thereof | 1 in force | to Oct 2036 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,435,026 | Solabegron Zwitterion and Uses Thereof held by B3AR Therapeutics, Inc. In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 10 patents in force now held by others · 5 patents ended · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.